Sarcopenia Is a Prognostic Factor of Adverse Effects and Mortality in Patients With Tumour: A Systematic Review and Meta‐Analysis
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: The relationship between sarcopenia and the prognosis of patients with tumours who received radio‐ and/or chemotherapy still needs to be determined. In this study, we aim to investigate the relationship between sarcopenia and adverse effects and mortality in patients with tumours that received radio‐ and/or chemotherapy, stratified by study design, tumour category, the method sarcopenia assessed, treatment options, study location and among other factors. Methods: PubMed, Web of Science and Embase were searched from inception to 15 August 2024, without language restrictions and with a manual search of references for additional articles retrieval. Cohort studies of ≥ 100 patients with tumours that evaluated the association between sarcopenia or muscle mass and the adverse effects or overall survival induced by radio‐ and/or chemotherapy were included. Results: Thirty‐nine studies were included, involving 8966 patients with tumours, including 3383 patients with sarcopenia. The pooled prevalence of sarcopenia in patients with tumours was 0.42 (95% CI 0.36–0.48, p < 0.001) overall. The prevalence of sarcopenia is higher in Oceania patients 0.60 (95% CI 0.28–0.89, p < 0.001), those with reproductive tumour 0.57 (95% CI 0.30–0.83, p < 0.001), and sarcopenia assessed by the lumbar‐skeletal muscle index 0.46 (95% CI 0.39–0.53, p < 0.001) than in other subgroups, but not show significant differences in sex. Sarcopenia was associated with an increased risk of adverse effects in patients who received radio‐ and/or chemotherapy, with a relative risk (RR) of 1.44 (95% CI 1.21–1.71, p < 0.001). Retrospective studies (RR = 1.49; 95% CI 1.24–1.79; p < 0.001), sarcopenia assessed by other methods (RR = 2.98; 95% CI 1.52–5.87; p < 0.001), and patients in Europe (RR = 1.92; 95% CI 1.15–3.22; p = 0.013), received chemoradiotherapy (RR = 1.47; 95% CI 1.23–1.76; p < 0.001), and with head and neck tumours (RR = 1.54; 95% CI 1.17–2.01; p = 0.010) had higher relative risk than other subgroups. Sarcopenia was also associated with reduced overall survival in patients with tumours, with a pooled hazard ratio (HR) of 1.66 (95% CI 1.40–1.96, p < 0.001). Prospective studies (HR = 1.72; 95% CI 0.97–3.07; p = 0.065), sarcopenia assessed by the cervical‐skeletal muscle index (HR = 2.66; 95% CI 1.73–4.09; p < 0.001), and patients in Asia (HR = 1.91; 95% CI 1.50–2.42; p < 0.001), received chemoradiotherapy (HR = 1.85; 95% CI 1.46–2.45; p < 0.001) and with head and neck tumours (HR = 2.35; 95% CI 1.88–2.95; p < 0.001) had higher HR than other subgroups. Conclusions: Sarcopenia was associated with a higher risk of adverse effects and mortality in patients with tumours received radio‐ and/or chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Studenski, S. A., Peters, K. W., Alley, D. E., Cawthon, P. M., McLean, R. R., Harris, T. B., Ferrucci, L., Guralnik, J. M., Fragala, M. S., Kenny, A. M., et al. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glu010 · Cited by 2,545
Sarcopenia: origins and clinical relevance
Rosenberg, I. H. (1997) · The Journal of Nutrition · doi:10.1093/jn/127.5.990s · Cited by 2,399 · cited 1×
“Sarcopenia is defined as a progressive and generalized skeletal muscle disorder, which increased the risk of adverse effects such as falls, fractures, disability and mortality [1–4], also recognized as a separate disease entity with the issuance of an ICD- 10-CM code [5].”
Muscaritoli, M., Anker, S. D., Argilés, J., Aversa, Z., Bauer, J. M., Biolo, G., Boirie, Y., Bosaeus, I., Cederholm, T., Costelli, P., et al. (2010) · Clinical Nutrition · doi:10.1016/j.clnu.2009.12.004 · Cited by 1,732 · cited 1×
“According to recent studies, cachexia and sarcopenia, which were previously confused, represent different aspects of muscle wasting [15, 16].”
Welcome to the ICD‐10 code for sarcopenia
Anker, S. D., Morley, J. E., & von Haehling, S. (2016) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12147 · Cited by 983
Effects of Aging on Muscle Fibre Type and Size
Deschenes, M. R. (2004) · Sports Medicine · doi:10.2165/00007256-200434120-00002 · Cited by 671 · cited 1×
“Aging leads to a reduction of skeletal muscle function in terms of muscle mass, strength and muscular endurance [11].”
Skeletal Muscle as Potential Central Link between Sarcopenia and Immune Senescence
Nelke, C., Dziewas, R., Minnerup, J., Meuth, S. G., & Ruck, T. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.10.034 · Cited by 437
Chiloiro, G., Cintoni, M., Palombaro, M., Romano, A., Reina, S., Pulcini, G., Corvari, B., Di Franco, S., Meldolesi, E., Egidi, G., et al. (2024) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2024.100789 · Cited by 21
Pielkenrood, B. J., van Urk, P. R., van der Velden, J. M., Kasperts, N., Verhoeff, J. J. C., Bol, G. H., Verkooijen, H. M., & Verlaan, J. J. (2020) · Acta Oncologica · doi:10.1080/0284186x.2019.1693059 · Cited by 17
Research works printed but not linked: 75
- 10.1002/jcsm.12483 · DOI · Paper page
- 10.1093/ageing/afab148 · DOI
- 10.1093/ageing/afq034 · DOI · Paper page
- 10.1016/j.jamda.2013.11.025 · DOI · Paper page
- 10.1016/j.jamda.2011.01.003 · DOI · Paper page
- 10.1002/jcsm.12783 · DOI · Paper page
- 10.1016/S0047-6374(02)00196-3 · DOI · Paper page
- 10.1007/978-3-319-57379-3_19 · DOI · Paper page
- 10.1016/j.clnu.2017.07.010 · DOI · Paper page
- 10.1016/j.ejca.2008.02.033 · DOI · Paper page
- 10.1177/0884533616680354 · DOI · Paper page
- 10.1002/jcsm.13082 · DOI
- 10.1097/SLA.0000000000005452 · DOI
- 10.1002/jcsm.13126 · DOI
- 10.1002/jcsm.12468 · DOI · Paper page
- 10.3390/ijms20102428 · DOI · Paper page
- 10.3390/ijms21010119 · DOI
- 10.1038/nrclinonc.2012.209 · DOI · Paper page
- 10.1016/j.ejca.2008.10.031 · DOI
- 10.1001/jama.283.15.2008 · DOI · Paper page
- 10.1007/s10654-010-9491-z · DOI · Paper page
- 10.1136/bmj.327.7414.557 · DOI · Paper page
- Irwig L., 1998, Bias in Meta‐Analysis Detected by a Simple, Graphical Test. Graphical Test Is Itself Biased, BMJ., 316, 470
- 10.1007/s10147-021-02062-z · DOI
- 10.1017/S0007114522000435 · DOI
- 10.1002/jso.27251 · DOI
- 10.1080/0284186X.2021.1983210 · DOI
- 10.1186/s12885-019-5319-8 · DOI
- 10.3389/fonc.2018.00457 · DOI
- 10.1002/jcsm.12234 · DOI · Paper page
- 10.1002/jcsm.12267 · DOI · Paper page
- 10.1016/j.radonc.2019.04.023 · DOI
- 10.1002/jcsm.12115 · DOI
- 10.1177/1758835920947612 · DOI
- 10.1002/cam4.2538 · DOI
- 10.21873/anticanres.14060 · DOI
- 10.3390/jpm11090936 · DOI
- 10.2169/internalmedicine.0900-22 · DOI
- 10.1080/01635581.2020.1870704 · DOI
- 10.1002/jcsm.13462 · DOI
- 10.3389/fonc.2024.1378762 · DOI
- 10.1158/1078-0432.CCR-18-0788 · DOI
- 10.1002/lary.29221 · DOI
- Li J. H., 2023, Relationships of Body Composition and Adipocytokines With Outcomes in Metastatic Castration‐Resistant Prostate Cancer Patients Receiving Docetaxel Chemotherapy, Asian Journal of Andrology., 25, 520
- 10.1007/s11604-024-01587-3 · DOI
- 10.1002/cam4.3604 · DOI
- 10.3389/fonc.2020.01576 · DOI
- 10.3390/nu14214448 · DOI
- 10.1016/j.radonc.2023.109764 · DOI
- 10.1186/s13014-021-01876-5 · DOI · Paper page
- 10.1186/s12876-022-02296-9 · DOI
- 10.1038/s41391-019-0186-6 · DOI
- 10.1371/journal.pone.0195406 · DOI
- 10.3390/cancers13040753 · DOI
- 10.1093/icvts/ivad020 · DOI
- 10.1002/jcsm.12487 · DOI
- 10.3389/fonc.2021.655071 · DOI
- 10.1016/j.anl.2021.03.021 · DOI
- 10.1016/j.radonc.2020.07.043 · DOI
- 10.1016/j.nut.2020.111135 · DOI
- 10.1080/17512433.2017.1347503 · DOI
- 10.1111/obr.12254 · DOI · Paper page
- 10.1002/jcsm.12168 · DOI
- 10.1002/jcsm.12235 · DOI
- 10.1186/s13395-019-0209-y · DOI
- 10.1158/1078-0432.CCR-08-2242 · DOI · Paper page
- 10.1158/1078-0432.CCR-16-2266 · DOI · Paper page
- 10.1093/annonc/mdx271 · DOI · Paper page
- 10.1038/s41598-022-27238-z · DOI
- 10.1016/j.clnesp.2022.04.009 · DOI
- 10.1007/s10549-019-05352-3 · DOI
- 10.1080/01635581.2022.2077387 · DOI
- 10.1016/j.ejso.2019.03.003 · DOI
- 10.1097/SLA.0000000000002679 · DOI · Paper page
- 10.3390/cancers14030785 · DOI
Metadata
- Authors
- Zhang, Y., Zhang, J., Zhan, Y., Pan, Z., Liu, Q., & Yuan, W.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2024-11-11
- Volume
- 15
- Issue
- 6
- Pages
- 2295-2310
- ISSN
- 2190-5991
- 2190-6009
- Cited by
- 37
- References
- 10
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.